Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction
Purpose of Review
In this review, we examine one of the ironies of American health care—that we pay more for disease management than disease prevention. Instead of preventing type 2 diabetes (T2DM) by treating its precursor, obesity, we fail to provide sufficient insurance coverage for weight management only to fund the more costly burden of overt T2DM.
There is a vital need for expanded insurance coverage to help foster a weight-centric approach to T2DM management. This includes broader coverage of anti-diabetic medications with evidence of cardiovascular risk reduction and mortality benefit, anti-obesity pharmacotherapy, bariatric surgery, weight loss devices, endoscopic bariatric therapies, and lifestyle interventions for the treatment of obesity.
The fundamental question to ask is why weight? Why wait to go after obesity until its end-stage sequelae cause intractable conditions? Instead of managing the complications of T2DM, consider preventing them by tackling obesity.
KeywordsObesity treatment Type 2 diabetes mellitus Diabetes prevention Evidence-based medicine Insurance coverage Access to care
Compliance with Ethical Standards
Conflict of Interest
Leon I. Igel, Katherine H. Saunders, and Joseph J. Fins declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 4.Centers for Disease Control and Prevention (2017). https://www.cdc.gov/diabetes/basics/diabetes.html. Accessed July 17, 2017.
- 6.Centers for Disease Control and Prevention. About underlying cause of death 1999–2015. CDC WONDER Database. http://wonder.cdc.gov/ucd-icd10.html. Accessed August 1, 2017.
- 9.American Medical Association Council on Science and Public Health, American Medical Association. Recognition of obesity as a disease. Resolution: 420(A-13). American Medical Association. May 2013. http://www.npr.org/documents/2013/jun/ama-resolution-obesity.pdf. Accessed August 1, 2017.
- 10.World Health Organization. WHO—obesity and overweight fact sheet. 2015. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed August 2, 2017.
- 19.Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.•• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. This study demonstrated that the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. CrossRefPubMedPubMedCentralGoogle Scholar
- 23.•• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. This study demonstrated that, in patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo. CrossRefPubMedGoogle Scholar
- 24.•• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. This study demonstrated that patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause. CrossRefPubMedGoogle Scholar
- 25.•• Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. This study demonstrated that patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo CrossRefPubMedGoogle Scholar
- 28.Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017 Jul 18;136(3):249–59.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20(2):344–51.CrossRefPubMedGoogle Scholar
- 30.Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709–17.CrossRefPubMedGoogle Scholar
- 31.Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23(2):207–38.CrossRefPubMedGoogle Scholar
- 35.Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–15.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977–83.CrossRefPubMedGoogle Scholar
- 40.Saxon D, Iwamoto S, Mettenbrink CJ, et al. Anti-obesity medication use in 2.2 million adults across 8 large healthcare organizations: 2009–2015. Obesity Week 2017. November 2, 2017; Washington, DC. Abstract T-OR-2070.Google Scholar
- 41.Wilson ER, Kyle TK, Nadglowski JF Jr, Stanford FC. Obesity coverage gap: consumers perceive low coverage for obesity treatments even when workplace wellness programs target BMI. Obesity (Silver Spring) 2017;25(2):370–377.Google Scholar
- 43.Gomez G, Stanford FCUS. Health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes. 2017; https://doi.org/10.1038/ijo.2017.287.
- 44.Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.CrossRefPubMedGoogle Scholar
- 46.Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.CrossRefPubMedGoogle Scholar
- 48.Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.CrossRefPubMedGoogle Scholar
- 49.Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.CrossRefPubMedGoogle Scholar
- 53.Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.CrossRefPubMedGoogle Scholar
- 56.Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Lent MR, Benotti PN, Mirshahi T, et al. All-cause and specific-cause mortality risk after Roux-en-Y gastric bypass in patients with and without diabetes. Diabetes Care. 2017. pii: dc170519.Google Scholar
- 67.American Society for Metabolic and Bariatric Surgery. New procedure estimates for bariatric surgery: what the numbers reveal. Connect - The Official News Magazine of ASMBS. May, 2014. http://connect.asmbs.org/may-2014-bariatric-surgery-growth.html
- 74.Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2017. pii: S0140–6736(17)33102–1.Google Scholar
- 75.Chaudhry ZW, Doshi RS, Mehta AK, Jacobs DK, Vakil RM, Lee CJ, et al. A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus. Obes Rev. 2016;17(8):758–69.CrossRefPubMedPubMedCentralGoogle Scholar
- 76.A study to evaluate the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors (CAMELLIA-TIMI). Available at: https://clinicaltrials.gov/show/NCT02019264.